Imatinib Completed Phase 2 Trials for Cancer, Ovarian Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00216112Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
NCT00510653Gleevec Study for Patients With Ovarian Cancer